{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T11:09:17Z","timestamp":1712747357024},"reference-count":11,"publisher":"American Association for Cancer Research (AACR)","issue":"18","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,9,15]]},"DOI":"10.1158\/0008-5472.can-16-2269","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T13:33:06Z","timestamp":1473946386000},"page":"5192-5194","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Commentary on \u201cRecombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2\/<i>neu<\/i> Overexpressing Human Breast Cancer Xenografts\u201d (A Follow Up)"],"prefix":"10.1158","volume":"76","author":[{"given":"John","family":"Mendelsohn","sequence":"first","affiliation":[{"name":"Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2016,9,15]]},"reference":[{"key":"2022061705003715200_bib1","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1073\/pnas.80.5.1337","article-title":"Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody","volume":"80","author":"Kawamoto","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061705003715200_bib2","first-page":"1002","article-title":"Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies","volume":"44","author":"Masui","year":"1984","journal-title":"Cancer Res"},{"key":"2022061705003715200_bib3","doi-asserted-by":"crossref","first-page":"7755","DOI":"10.1016\/S0021-9258(17)42857-2","article-title":"Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity","volume":"259","author":"Gill","year":"1984","journal-title":"J Biol Chem"},{"key":"2022061705003715200_bib4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0092-8674(85)80050-7","article-title":"Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies","volume":"41","author":"Drebin","year":"1985","journal-title":"Cell"},{"key":"2022061705003715200_bib5","first-page":"1165","article-title":"p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor","volume":"9","author":"Hudziak","year":"1989","journal-title":"Mol Cell Biol"},{"key":"2022061705003715200_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/jnci\/83.2.97","article-title":"Phase I and imaging trial of Indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma","volume":"83","author":"Divgi","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"2022061705003715200_bib7","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/jnci\/85.16.1327","article-title":"Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies","volume":"85","author":"Baselga","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2022061705003715200_bib8","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2000.18.4.904","article-title":"Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin","volume":"18","author":"Baselga","year":"2000","journal-title":"J Clin Oncol"},{"key":"2022061705003715200_bib9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","article-title":"Phase II Study of Weekly Intravenous Recombinant Humanized anti-p185HER2 monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer","volume":"14","author":"Baselga","year":"1996","journal-title":"J Clin Oncol"},{"key":"2022061705003715200_bib10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"2022061705003715200_bib11","first-page":"2825","article-title":"Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2\/neu overexpressing human breast cancer xenografts.","volume":"58","author":"Baselga","year":"1998","journal-title":"Cancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/76\/18\/5192\/2739807\/5192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/76\/18\/5192\/2739807\/5192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T15:31:25Z","timestamp":1655479885000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/76\/18\/5192\/613897\/Commentary-on-Recombinant-Humanized-Anti-HER2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,15]]},"references-count":11,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2016,9,15]]},"published-print":{"date-parts":[[2016,9,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-16-2269","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,15]]}}}